Literature DB >> 11414126

The Danish Multiple Sclerosis Registry. History, data collection and validity.

N Koch-Henriksen1, S Rasmussen, E Stenager, M Madsen.   

Abstract

The Danish Multiple Sclerosis Registry was formally established in 1956 but started operating in 1949 with a nationwide prevalence survey. Since then, the Registry has continued collecting data on new and old cases of multiple sclerosis (MS) or suspected MS from multiple sources. The Registry reclassifies cases according to standardized diagnostic criteria (currently those of Poser et al). A total of 14,441 cases fulfilling the diagnostic criteria had been registered at the most recently completed follow-up by 1 January 1997; 10,851 had onset from 1948 to 1996 and 3560 before 1948. The completeness has formerly been estimated at about 90%, higher for cohorts with older onset and lower for cohorts with onset close to follow-up. The estimated validity of the diagnosis for autopsy cases classified as definite MS in the Registry is 94%. A long-term nationwide Registry has proved to be a valuable instrument for monitoring incidence and prevalence, analysing survival, performing genetic analysis, providing unselected patient samples for clinical analyses, performing case-control studies and prospective studies and estimating the need for treatment and care.

Entities:  

Mesh:

Year:  2001        PMID: 11414126

Source DB:  PubMed          Journal:  Dan Med Bull        ISSN: 0907-8916


  11 in total

Review 1.  Quality of life in multiple sclerosis: determinants, measurement, and use in clinical practice.

Authors:  Deborah M Miller; Rebecca Allen
Journal:  Curr Neurol Neurosci Rep       Date:  2010-09       Impact factor: 5.081

2.  Childhood body mass index and multiple sclerosis risk: a long-term cohort study.

Authors:  Kassandra L Munger; Joan Bentzen; Bjarne Laursen; Egon Stenager; Nils Koch-Henriksen; Thorkild I A Sørensen; Jennifer L Baker
Journal:  Mult Scler       Date:  2013-04-02       Impact factor: 6.312

3.  Smoking and increased risk of multiple sclerosis: parallel trends in the sex ratio reinforce the evidence.

Authors:  Natalia Palacios; Alvaro Alonso; Henrik Brønnum-Hansen; Alberto Ascherio
Journal:  Ann Epidemiol       Date:  2011-05-07       Impact factor: 3.797

4.  Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.

Authors:  Anja Thormann; Melinda Magyari; Nils Koch-Henriksen; Bjarne Laursen; Per Soelberg Sørensen
Journal:  J Neurol       Date:  2016-10-03       Impact factor: 4.849

Review 5.  National MS registries.

Authors:  Peter Flachenecker; Kristin Stuke
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

6.  Risk of fractures in patients with multiple sclerosis: a population-based cohort study.

Authors:  M T Bazelier; T-P van Staa; B M J Uitdehaag; C Cooper; H G M Leufkens; P Vestergaard; R M C Herings; F de Vries
Journal:  Neurology       Date:  2012-05-16       Impact factor: 9.910

7.  Validation of the danish version of functional assessment of multiple sclerosis: a quality of life instrument.

Authors:  Jan Sørensen; Jette Bay; Torben Damsgaard; Elsebeth Heeley; Ida Rostgaard; Brita Løvendahl; Finn Boesen
Journal:  Mult Scler Int       Date:  2011-10-30

8.  Mobile phones and multiple sclerosis--a nationwide cohort study in Denmark.

Authors:  Aslak Harbo Poulsen; Egon Stenager; Christoffer Johansen; Joan Bentzen; Søren Friis; Joachim Schüz
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

Review 9.  Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.

Authors:  Jeffrey A Cohen; Maria Trojano; Ellen M Mowry; Bernard Mj Uitdehaag; Stephen C Reingold; Ruth Ann Marrie
Journal:  Mult Scler       Date:  2019-11-28       Impact factor: 6.312

10.  Pediatric acquired demyelinating syndromes: a nationwide validation study of the Danish National Patient Register.

Authors:  Magnus Spangsberg Boesen; Melinda Magyari; Alfred Peter Born; Lau Caspar Thygesen
Journal:  Clin Epidemiol       Date:  2018-04-10       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.